|TG Therapeutics, Inc.|
3 Columbus Circle
United States - Map
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two therapies targeting hematological malignancies. Its therapies include TG-1101, a chimeric glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency. The company is based in New York, New York.
|TG Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 7. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 2; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Michael S. Weiss Esq.,
Exec. Chairman, Interim Chief Exec. Officer and Pres
|Mr. Sean A. Power CPA,
Chief Financial Officer, Principal Accounting Officer, Treasurer and Sec.
|Dr. Robert Niecestro Ph.D.,
Exec. VP of Clinical and Regulatory
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|